Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

Core Insights - The Alliance for Genomic Discovery (AGD) has expanded its dataset to over 312,000 whole genomes with longitudinal clinical data, with Regeneron Genetics Center (RGC) joining as the tenth member [1] - A new initiative will add 50,000 whole genomes paired with proteomic data, with GSK being one of the first participants in this multiomic expansion [1] - The integration of high-quality clinical and genomic data with advanced AI is expected to enhance drug discovery and patient outcomes [1] Dataset Expansion - The AGD dataset is now one of the largest collections of whole genome sequences, enriched with clinical data from a leading academic medical center [1] - The addition of RGC will significantly scale the database, which already includes nearly 3 million sequenced exomes and de-identified electronic health records (EHRs) [1] - The dataset aims to facilitate precise disease cohort definitions and has already contributed to discoveries in autoimmune diseases and obesity [1] Proteomics Initiative - The new dataset will consist of 50,000 paired whole-genome and proteomic samples, enhancing the molecular depth of the AGD dataset [1] - This initiative is designed to accelerate target discovery and therapy development by providing deeper biological insights [1] - The diverse genetic ancestry within AGD allows for the study of population-specific genetic variants and their associated proteins [1] Collaboration and Goals - RGC aims to uncover large-effect protective genetic factors to identify high-confidence drug targets [1] - The collaboration reflects ongoing partnerships with Illumina and the biopharma community to build large-scale population genomics consortia [1] - The integration of proteomics with comprehensive datasets is expected to pinpoint drug targets linked to human diseases [1]